Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Targeted Therapies in Neuroendocrine Tumors

March 14th 2013

Emerging Treatment Options in Neuroendocrine Tumors

March 14th 2013

Role of Somatostatin Analogs in Neuroendocrine Tumors

March 14th 2013

Surgical Treatment of Neuroendocrine Tumors

March 14th 2013

The Genetics Behind Familial Neuroendocrine Tumors

March 14th 2013

Techniques for Diagnosing Neuroendocrine Tumors

March 14th 2013

Challenges in the Diagnosis of Neuroendocrine Tumors

March 14th 2013

The Role of Biomarkers in Neuroendocrine Tumors

March 14th 2013

Histological Classification of Neuroendocrine Tumors

March 14th 2013

Neuroendocrine Tumors: Introduction and Overview

March 14th 2013

Making Time for Innovation: Myeloma Expert Sets Brisk Pace of Discovery

March 11th 2013

Working in the laboratory and the clinic, Shaji K. Kumar, MD, has made a discovery: that there aren't enough hours in a day.

Dr. Ron Bose on HER2 Gene Mutations in Breast Cancer

March 8th 2013

Ron Bose, MD, PhD, from the Siteman Cancer Center, discusses the prevalence of HER2 gene mutations in patients diagnosed with breast cancer.

EGFR's Evolution: New Insights Refine Role of Mutation in NSCLC

March 1st 2013

Despite all we have learned about the importance of sensitizing EGFR mutations in defining the management of advanced NSCLC, our education regarding the relevance of this molecular target in optimizing clinical outcomes continues.

Notch Holds Promise, but Presents Obstacles as Cancer Target

March 1st 2013

Benjamin W. Purow, MD, a researcher whose focus is on glioblastomas, discusses the Notch pathway and the development of Notch-targeted anticancer agents.

EGFR Mutation Not a Prognostic Factor for NSCLC

February 28th 2013

Although the presence of an EGFR mutation is a predictive marker for response to EGFR tyrosine kinase inhibitor therapy in patients with non-small cell lung cancer, the mutation is not a prognostic factor.

Notch Signaling: Tackling a Complex Pathway With a New Generation of Agents

February 27th 2013

Notch-targeted agents that were initially intended for the treatment of Alzheimer disease are now being examined for their possible anticancer activity.

Dr. Kamat on a Molecular Definition of BCG Failure

February 26th 2013

Ashish M. Kamat, MD, from MD Anderson Cancer Center, discusses enhancing clinical trial recruitment through a novel definition of BCG therapy failure in patients with nonmuscle invasive bladder cancer.

Targeted Therapies, Multidrug Regimens, and Standardized Drug Development Efforts Needed in Nonmuscle-Invasive Bladder Cancer

February 26th 2013

Collaborative and standardized efforts to develop and evaluate novel drugs are necessary to ultimately provide effective long-term treatment for nonmuscle-invasive bladder cancer.

Regorafenib Approved to Treat GIST

February 25th 2013

The FDA approved regorafenib for the treatment of gastrointestinal stromal tumors that cannot be removed surgically and no longer respond to other FDA-approved treatments for the disease.

Dr. Gradishar on Enriching Targeted Therapy Trials

February 19th 2013

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, describes the need to enrich the patient population in a clinical trial that is investigating a novel targeted therapy.